Loading organizations...
Key people at Vesalius Biocapital IV.
Vesalius Biocapital IV operates as a European venture capital fund, strategically deploying capital into later-stage life sciences companies. Its investment focus spans drug development, medical devices, diagnostics, and eHealth/mHealth, predominantly within the European market. The fund targets enterprises that address significant unmet medical and market needs, fortified by strong intellectual property.
Vesalius Biocapital, the overarching firm, was established in 2007, with Stéphane Verdood noted as a founding partner. This foundation arose from a clear understanding of the substantial capital demands and growth potential inherent in the European life sciences sector. This foundational insight propelled the creation of a specialized investment platform dedicated to advancing innovative human health companies.
The fund's investments directly benefit patients globally by fostering advanced therapies and novel health technologies. Vesalius Biocapital IV is committed to driving innovation in human health, aiming for improved diagnostics, superior patient outcomes, and effective solutions for global healthcare challenges. The firm proactively builds a diversified portfolio to achieve its forward-looking mission.
Key people at Vesalius Biocapital IV.
Vesalius Biocapital IV is a Luxembourg‑based life‑sciences venture capital fund (Fund IV of the Vesalius platform) that raises and deploys growth and late‑preclinical/early‑clinical capital into European biopharma, medical devices/diagnostics and digital health companies, targeting a diversified portfolio of roughly 10–15 companies with a fund target of about €150M and an initial close of >€95M that included the European Investment Fund as an investor[3][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Health‑Tech Landscape
Quick Take & Future Outlook
Quick factual notes: Vesalius Biocapital IV completed a first close in June 2023 with >€95M in commitments and targets ~€150M overall; the fund emphasizes first/best‑in‑class drug development and digital health across Europe and counts the European Investment Fund among its early backers[3][2].